S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:ATHA

Athira Pharma Competitors

$19.29
-1.31 (-6.36 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.86
Now: $19.29
$20.79
50-Day Range
$20.06
MA: $22.47
$27.99
52-Week Range
$15.79
Now: $19.29
$34.79
Volume735,032 shs
Average Volume483,301 shs
Market Capitalization$626.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Athira Pharma (NASDAQ:ATHA) Vs. SRNE, ALVR, KYMR, BCRX, BLUE, and VCEL

Should you be buying ATHA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Athira Pharma, including Sorrento Therapeutics (SRNE), AlloVir (ALVR), Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), and Vericel (VCEL).

Sorrento Therapeutics (NASDAQ:SRNE) and Athira Pharma (NASDAQ:ATHA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Sorrento Therapeutics and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sorrento Therapeutics-698.01%-314.06%-43.60%
Athira PharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sorrento Therapeutics and Athira Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sorrento Therapeutics00403.00
Athira Pharma00403.00

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 226.33%. Athira Pharma has a consensus price target of $42.50, indicating a potential upside of 120.32%. Given Sorrento Therapeutics' higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Athira Pharma.

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sorrento Therapeutics and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Athira Pharma has lower revenue, but higher earnings than Sorrento Therapeutics.

Summary

Athira Pharma beats Sorrento Therapeutics on 5 of the 8 factors compared between the two stocks.

Athira Pharma (NASDAQ:ATHA) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for Athira Pharma and AlloVir, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athira Pharma00403.00
AlloVir00403.00

Athira Pharma currently has a consensus price target of $42.50, indicating a potential upside of 120.32%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 41.18%. Given Athira Pharma's higher probable upside, equities research analysts plainly believe Athira Pharma is more favorable than AlloVir.

Valuation and Earnings

This table compares Athira Pharma and AlloVir's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A$-5,160,000.00N/AN/A
AlloVirN/AN/AN/AN/AN/A

Profitability

This table compares Athira Pharma and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Athira PharmaN/AN/AN/A
AlloVirN/AN/AN/A

Institutional & Insider Ownership

66.7% of Athira Pharma shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats AlloVir on 2 of the 3 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Athira Pharma (NASDAQ:ATHA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Kymera Therapeutics and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Athira PharmaN/AN/AN/A

Institutional & Insider Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Kymera Therapeutics and Athira Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kymera Therapeutics and Athira Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02402.67
Athira Pharma00403.00

Kymera Therapeutics currently has a consensus target price of $50.3333, indicating a potential upside of 9.75%. Athira Pharma has a consensus target price of $42.50, indicating a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Kymera Therapeutics.

Summary

Athira Pharma beats Kymera Therapeutics on 3 of the 3 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares BioCryst Pharmaceuticals and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Athira PharmaN/AN/AN/A

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Athira Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Athira Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Athira Pharma00403.00

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than BioCryst Pharmaceuticals.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats BioCryst Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares bluebird bio and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
bluebird bio-256.84%-45.78%-35.14%
Athira PharmaN/AN/AN/A

Earnings and Valuation

This table compares bluebird bio and Athira Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Athira Pharma has lower revenue, but higher earnings than bluebird bio.

Analyst Ratings

This is a breakdown of current ratings for bluebird bio and Athira Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
bluebird bio013402.24
Athira Pharma00403.00

bluebird bio presently has a consensus price target of $68.4667, suggesting a potential upside of 145.05%. Athira Pharma has a consensus price target of $42.50, suggesting a potential upside of 120.32%. Given bluebird bio's higher probable upside, equities research analysts plainly believe bluebird bio is more favorable than Athira Pharma.

Insider & Institutional Ownership

94.3% of bluebird bio shares are held by institutional investors. Comparatively, 66.7% of Athira Pharma shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Athira Pharma beats bluebird bio on 5 of the 9 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Vericel and Athira Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Athira PharmaN/AN/AN/A

Earnings & Valuation

This table compares Vericel and Athira Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50
Athira PharmaN/AN/A$-5,160,000.00N/AN/A

Athira Pharma has lower revenue, but higher earnings than Vericel.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Athira Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Athira Pharma00403.00

Vericel presently has a consensus target price of $49.00, suggesting a potential upside of 21.26%. Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Vericel.

Insider and Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vericel beats Athira Pharma on 7 of the 10 factors compared between the two stocks.


Athira Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.